{"id":"tritanrix-hepb","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fever"},{"rate":"null","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by stimulating the body's immune system to produce antibodies against these pathogens, providing long-term immunity. The vaccine contains inactivated or attenuated forms of the pathogens, which are unable to cause disease but still trigger an immune response. This immune response helps the body to recognize and fight off future infections.","oneSentence":"Tritanrix-HepB is a vaccine that protects against diphtheria, tetanus, pertussis, hepatitis B, and haemophilus influenzae type b.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:14.248Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Protection against diphtheria, tetanus, pertussis, hepatitis B, and haemophilus influenzae type b in infants and children"}]},"trialDetails":[{"nctId":"NCT00263666","phase":"PHASE2","title":"A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-16","conditions":"Infections, Rotavirus","enrollment":100},{"nctId":"NCT00136604","phase":"PHASE3","title":"Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-22","conditions":"Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B","enrollment":617},{"nctId":"NCT00228917","phase":"PHASE3","title":"Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06-16","conditions":"Whole Cell Pertussis, Tetanus, Hepatitis B","enrollment":798},{"nctId":"NCT00814710","phase":"PHASE3","title":"Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-07","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae","enrollment":360},{"nctId":"NCT02207816","phase":"PHASE3","title":"An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-18","conditions":"Malaria","enrollment":3084},{"nctId":"NCT00866619","phase":"PHASE3","title":"Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-27","conditions":"Malaria","enrollment":15459},{"nctId":"NCT01098474","phase":"PHASE2","title":"Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-07","conditions":"Tuberculosis","enrollment":301},{"nctId":"NCT01262872","phase":"PHASE2","title":"Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-09","conditions":"Infections, Streptococcal","enrollment":1320},{"nctId":"NCT01175083","phase":"PHASE3","title":"Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-06-01","conditions":"Infections, Streptococcal","enrollment":300},{"nctId":"NCT00547248","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-22","conditions":"Infections, Streptococcal","enrollment":756},{"nctId":"NCT00344318","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-07","conditions":"Infections, Streptococcal","enrollment":806},{"nctId":"NCT00829010","phase":"PHASE3","title":"Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02-17","conditions":"Infections, Streptococcal","enrollment":489},{"nctId":"NCT00436007","phase":"PHASE2","title":"Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-30","conditions":"Malaria","enrollment":511},{"nctId":"NCT00317135","phase":"PHASE3","title":"Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-12-11","conditions":"Diphtheria, Hepatitis B, Whole Cell Pertussis","enrollment":500},{"nctId":"NCT00317187","phase":"PHASE3","title":"Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-06-08","conditions":"Hepatitis B, Diphtheria, Whole Cell Pertussis","enrollment":500},{"nctId":"NCT01231503","phase":"PHASE2","title":"Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-13","conditions":"Malaria","enrollment":480},{"nctId":"NCT00291343","phase":"PHASE3","title":"Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-01","conditions":"Infections, Meningococcal","enrollment":296},{"nctId":"NCT00158756","phase":"PHASE3","title":"Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09-12","conditions":"Hepatitis B","enrollment":308},{"nctId":"NCT00169442","phase":"PHASE3","title":"Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-02-10","conditions":"Whole Cell Pertussis, Diphtheria, Hepatitis B","enrollment":745},{"nctId":"NCT00317109","phase":"PHASE3","title":"Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04-19","conditions":"Infections, Meningococcal","enrollment":168},{"nctId":"NCT00473668","phase":"PHASE3","title":"Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-01","conditions":"Whole Cell Pertussis, Haemophilus Influenzae Type b, Tetanus","enrollment":300},{"nctId":"NCT00197275","phase":"PHASE3","title":"Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02","conditions":"Tetanus, Hepatitis B, Haemophilus Influenzae Type b","enrollment":800},{"nctId":"NCT00332566","phase":"PHASE3","title":"Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06","conditions":"Hepatitis B, Whole Cell Pertussis, Tetanus","enrollment":148},{"nctId":"NCT00317122","phase":"PHASE3","title":"Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10","conditions":"Diphtheria; Haemophilus Influenzae Type b; Hepatitis B; Tetanus; Whole Cell Pertussis","enrollment":192},{"nctId":"NCT00290303","phase":"PHASE3","title":"Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-05","conditions":"Haemophilus Influenzae Type b, Diphtheria, Whole Cell Pertussis","enrollment":996},{"nctId":"NCT01061541","phase":"PHASE2","title":"Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-08","conditions":"Haemophilus Influenzae Type b","enrollment":192},{"nctId":"NCT00514709","phase":"PHASE3","title":"Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-09","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1843},{"nctId":"NCT01003431","phase":"PHASE3","title":"A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12","conditions":"Rotavirus Gastroenteritis, Diphtheria, Tetanus","enrollment":""},{"nctId":"NCT00313911","phase":"PHASE3","title":"Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-07","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":2133},{"nctId":"NCT00343889","phase":"PHASE3","title":"Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-08","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":379},{"nctId":"NCT00534833","phase":"PHASE3","title":"Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-09","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":362},{"nctId":"NCT00348881","phase":"PHASE3","title":"Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-06","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":2133},{"nctId":"NCT01357720","phase":"PHASE4","title":"Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vaccination","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2011-05","conditions":"Diphtheria, Pertussis, Tetanus","enrollment":400},{"nctId":"NCT00291967","phase":"PHASE2","title":"Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-11","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":525}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DTPw-HBV vaccine","DTPw-HBV"],"phase":"phase_3","status":"active","brandName":"Tritanrix-HepB","genericName":"Tritanrix-HepB","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Tritanrix-HepB is a vaccine that protects against diphtheria, tetanus, pertussis, hepatitis B, and haemophilus influenzae type b. Used for Protection against diphtheria, tetanus, pertussis, hepatitis B, and haemophilus influenzae type b in infants and children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}